세계의 PEG화 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for PEGylation Market is presumed to reach the market size of nearly USD 5.8 Billion by 2032 from USD 2.03 Billion in 2023 with a CAGR of 12.36% under the study period 2024-2032.

PEGylation (or pegylation) is the process of attaching or amalgamating polyethylene glycol (PEG, also known as macrogol in pharmacy) polymer chains to molecules and macrostructures, such as medication, therapeutic protein, or vesicle, in both covalent and non-covalent ways. PEGylation is commonly accomplished by incubating the target molecule with a reactive PEG derivative. The covalent attachment of PEG to a medication or therapeutic protein can ''''hide'''' the agent from the host's immune system (reduce immunogenicity and antigenicity) and enhance its hydrodynamic size (size in solution), which extends its circulation duration by reducing renal clearance. Hydrophobic medicines and proteins can also be PEGylated to make them water-soluble.

MARKET DYNAMICS

Increased R&D investments by pharmaceutical and biopharmaceutical companies, expansion in the biologics industry, rising prevalence of lifestyle illness, and increased attention and awareness on improving protein stability and circulation half-life are projected to drive market growth. Furthermore, as the number of people infected with chronic diseases rise, the PEGylation market will be fueled by the increased usage of PEGylated protein to treat various chronic diseases. PEGylated molecules provide many advantages, including a longer half-life, decreased toxicity, lower immunogenicity, and increased proteolytic protection, all contribute to the market's continued expansion. But on the other side, rising PEGylation process costs and the patent expiration of certain medications are expected to stifle market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of PEGylation. The growth and trends of PEGylation industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the PEGylation market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product & Services

• Consumables
• Services

By Type

• Colony-stimulating Factor
• Interferons
• Erythropoietin
• Recombinant Factor VII
• Others

By Application

• Cancer
• Autoimmune Diseases
• Hepatitis
• Multiple Sclerosis
• Hemophilia
• Gastrointestinal Disorders
• Others

By End-user

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutes
• PEGylated Proteins

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the PEGylation market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PEGylation market include Thermo Fisher Scientific Inc., Abcam Plc, Enzon Pharmaceuticals Inc., Merck KGaA, Celares GmbH, Profacgen, Creative PEGworks, NOF America Corp., Aurigene Pharmaceutical Services Ltd., Laysan Bio Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PEGYLATION - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product & Services
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By End-user
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PEGYLATION MARKET ANALYSIS BY PRODUCT & SERVICES

• 5.1. Overview By Product & Services
• 5.2. Historical and Forecast Data Analysis By Product & Services
• 5.3. Consumables Historic and Forecast Sales By Regions
• 5.4. Services Historic and Forecast Sales By Regions

6. GLOBAL PEGYLATION MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data Analysis By Type
• 6.3. Colony-stimulating Factor Historic and Forecast Sales By Regions
• 6.4. Interferons Historic and Forecast Sales By Regions
• 6.5. Erythropoietin Historic and Forecast Sales By Regions
• 6.6. Recombinant Factor VII Historic and Forecast Sales By Regions
• 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PEGYLATION MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Cancer Historic and Forecast Sales By Regions
• 7.4. Autoimmune Diseases Historic and Forecast Sales By Regions
• 7.5. Hepatitis Historic and Forecast Sales By Regions
• 7.6. Multiple Sclerosis Historic and Forecast Sales By Regions
• 7.7. Hemophilia Historic and Forecast Sales By Regions
• 7.8. Gastrointestinal Disorders Historic and Forecast Sales By Regions
• 7.9. Others Historic and Forecast Sales By Regions

8. GLOBAL PEGYLATION MARKET ANALYSIS BY END-USER

• 8.1. Overview By End-user
• 8.2. Historical and Forecast Data Analysis By End-user
• 8.3. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
• 8.4. Contract Research Organizations Historic and Forecast Sales By Regions
• 8.5. Academic & Research Institutes Historic and Forecast Sales By Regions
• 8.6. PEGylated Proteins Historic and Forecast Sales By Regions

9. GLOBAL PEGYLATION MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PEGYLATION COMPANIES

• 10.1. PEGylation Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF PEGYLATION INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Thermo Fisher Scientific Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Abcam Plc
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Enzon Pharmaceuticals Inc.
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Merck KGaA
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Celares GmbH
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Profacgen
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Creative PEGworks
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. NOF America Corp.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Aurigene Pharmaceutical Services Ltd.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Laysan Bio Inc
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies